• Adaptimmune Therapeutics (NASDAQ:ADAP) announced positive data from the primary analysis of its mid-stage trial of lete-cel in people with synovial sarcoma or myxoid/round cell liposarcoma who received previous anthracycline-based therapy.
• The company said 42% of people with advanced or metastatic synovial

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。